Clinical trial
An Open-Label, Multicenter, Single-Arm, Phase II Study to Assess the Efficacy and Safety of Alectinib in Patients With ALK-Rearranged Non-Small Cell Lung Cancer After Disease Progression on Prior ALK Inhibitor Therapy
NCT03155009 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-Label, Multicenter, Single-Arm, Phase II Study to Assess the Efficacy and Safety of Alectinib in Patients With ALK-Rearranged Non-Small Cell Lung Cancer After Disease Progression on Prior ALK Inhibitor Therapy
- Lead sponsor
- Hoffmann-La Roche
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- July 10, 2017
- Completion date
- September 26, 2019
- Enrollment
- 44 (actual)
- Sites
- 16
Conditions
As the registry lists them; a condition with its own page is linked.